Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Revolution Medicines (RVMD) Shares Outstanding (2018 - 2025)

Historic Shares Outstanding for Revolution Medicines (RVMD) over the last 8 years, with Q3 2025 value amounting to $189.7 million.

  • Revolution Medicines' Shares Outstanding rose 1309.26% to $189.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $189.7 million, marking a year-over-year increase of 1309.26%. This contributed to the annual value of $185.9 million for FY2024, which is 1288.73% up from last year.
  • Revolution Medicines' Shares Outstanding amounted to $189.7 million in Q3 2025, which was up 1309.26% from $186.9 million recorded in Q2 2025.
  • Revolution Medicines' Shares Outstanding's 5-year high stood at $189.7 million during Q3 2025, with a 5-year trough of $73.4 million in Q1 2021.
  • Its 5-year average for Shares Outstanding is $124.1 million, with a median of $109.1 million in 2023.
  • Per our database at Business Quant, Revolution Medicines' Shares Outstanding soared by 107.93% in 2022 and then soared by 8213.82% in 2023.
  • Over the past 5 years, Revolution Medicines' Shares Outstanding (Quarter) stood at $74.1 million in 2021, then grew by 21.94% to $90.4 million in 2022, then surged by 82.14% to $164.7 million in 2023, then increased by 12.89% to $185.9 million in 2024, then increased by 2.05% to $189.7 million in 2025.
  • Its last three reported values are $189.7 million in Q3 2025, $186.9 million for Q2 2025, and $186.3 million during Q1 2025.